Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune microenvironment and noncoding RNA shape early colorectal carcinogenesis in patients with premalignant lesions.

Science translational medicine·2026
Same author

A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients.

Cancers·2026
Same author

Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r/r lymphoma.

British journal of haematology·2026
Same author

Enhancing the accuracy of molecular classification of pediatric CNS tumors: a dual-classifier approach using DNA methylation profiling.

Frontiers in oncology·2026
Same author

Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.

Journal for immunotherapy of cancer·2025
Same author

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same journal

The lncRNA-m6A axis in cancer: a bidirectional regulatory network in tumor progression and therapeutic resistance.

Journal of translational medicine·2026
Same journal

Repurposing cepharanthine as a radiosensitizer in esophageal squamous cell carcinoma through dual metabolic intervention and direct targeting of p70s6K.

Journal of translational medicine·2026
Same journal

Cellular crosstalk and signaling networks in the rheumatoid arthritis synovial microenvironment.

Journal of translational medicine·2026
Same journal

Pilot spatial transcriptomics of dental pulpitis suggests immune-fibroblast profiling linked to reversibility.

Journal of translational medicine·2026
Same journal

Beyond semen analysis: in men with normal semen parameters telomere attrition and oxidative imbalance distinguish those fertile from those with infertility.

Journal of translational medicine·2026
Same journal

Dual-block HER2 assessment reveals clinically relevant intratumoral heterogeneity in gynecologic cancers: a single-center landscape analysis.

Journal of translational medicine·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

IRF5 gene polymorphisms in melanoma.

Lorenzo Uccellini1, Valeria De Giorgi, Yingdong Zhao

  • 1Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans-NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA. uccellinilorenzo@gmail.com

Journal of Translational Medicine
|August 23, 2012
PubMed
Summary
This summary is machine-generated.

Interferon regulatory factor (IRF) 5 gene variations may predict melanoma treatment success. Specific IRF5 polymorphisms are linked to patient response to adoptive immunotherapy using tumor infiltrating lymphocytes (TILs).

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Related Experiment Videos

Last Updated: May 19, 2026

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Area of Science:

  • Immunology
  • Genetics
  • Oncology

Background:

  • Interferon regulatory factor (IRF)-5 is a transcription factor crucial for type I interferon signaling.
  • Germline variants in IRF5 are implicated in autoimmune disease development.
  • Autoimmunity and melanoma immunotherapy response share observed links.

Purpose of the Study:

  • To investigate the association between Interferon regulatory factor (IRF)-5 gene polymorphisms and melanoma patient responsiveness to adoptive therapy with tumor infiltrating lymphocytes (TILs).

Main Methods:

  • Genotyping of 140 tumor-infiltrating lymphocytes (TILs) for five IRF5 gene variations (four SNPs, one indel).
  • Assessing gene expression profiles of TILs, 112 melanoma metastases, and 9 melanoma cell lines using Affymetrix arrays.
  • Analyzing associations between IRF5 genotypes and therapy response.

Main Results:

  • A specific IRF5 polymorphism (rs10954213, lack of A allele) was significantly associated with non-response to TILs therapy (p < 0.005).
  • Other linked IRF5 polymorphisms showed similar trends.
  • Differential gene expression based on IRF5 genotype in cell lines predicted therapy response in melanoma metastases, suggesting IRF5 influences melanoma biology and immune response.

Conclusions:

  • This study establishes the first link between IRF5 gene polymorphism and melanoma immune response to adoptive cell therapy.
  • Findings suggest a shared genetic basis for autoimmunity and melanoma immune responsiveness.
  • IRF5 genotype may impact melanoma's intrinsic characteristics, affecting immunotherapy outcomes.